Literature DB >> 9700971

Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent.

H Sakamoto1, K Matsumoto, Y Ohno, M Nakamura.   

Abstract

We examined the anxiolytic potential of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent, and compared its effects with those of the standard anxiolytic diazepam and the conventional antipsychotic haloperidol by using conditioned defensive burying (CDB) and social interaction (SI) tests in rats. The tests were conducted 1 h after oral administration of the drug. Diazepam inhibited CDB specifically directed toward a probe previously associated with brief electric shock and increased the time spent in SI by pairs of naive rats in a brightly illuminated novel environment. Perospirone mimicked the effects of diazepam by dose dependently suppressing CDB and facilitating SI. In contrast, haloperidol failed to inhibit CDB or increase SI. These results suggested that, unlike the conventional antipsychotic haloperidol, perospirone exerts anxiolytic-like effects in animal models with different motivational and emotional states. A braoder efficacy of perospirone for the treatment of anxiety and related symptoms in schizophrenia is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700971     DOI: 10.1016/s0091-3057(98)00068-9

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  2 in total

1.  Genetic polymorphisms in dopamine- and serotonin-related genes and treatment responses to risperidone and perospirone.

Authors:  Atsushi Tsutsumi; Tetsufumi Kanazawa; Hiroki Kikuyama; Gaku Okugawa; Hiroyuki Uenishi; Toshio Miyamoto; Naoki Matsumoto; Jun Koh; Kazuhiro Shinosaki; Toshifumi Kishimoto; Hiroshi Yoneda; Toshihiko Kinoshita
Journal:  Psychiatry Investig       Date:  2009-08-03       Impact factor: 2.505

2.  The alkaloid alstonine: a review of its pharmacological properties.

Authors:  E Elisabetsky; L Costa-Campos
Journal:  Evid Based Complement Alternat Med       Date:  2006-01-16       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.